Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload

作者: F. Nolte , B. Höchsmann , A. Giagounidis , M. Lübbert , U. Platzbecker

DOI: 10.1007/S00277-012-1594-Z

关键词:

摘要: The majority of patients with myelodysplastic syndrome (MDS) present anemia and will become dependent on regular transfusions packed red blood cells (PRBC) the risk iron overload (IOL). Liver content best reflects total body content, measurement liver concentration (LIC) by MRI is a validated tool for detection, but data in MDS rather limited. Here we results multi-center trial evaluating efficacy safety deferasirox (DFX) low intermediate-1 transfusion-dependent IOL. Three transfusion frequency > 4 units PRBC per month were initially treated 30 mg/kg/day while 46 lower burden was initiated at 20 mg/kg/day, due to patient related reasons one received DFX dose 6 mg/kg/day only. LIC measured baseline end study using method St. Pierre et al. intention treat population consisted 50 (28 male; 22 female) median age 69 years who duration 354 days. Mean daily 19 mg/kg/day. Median serum ferritin level (SF) 2,447 ng/mL decreased 1,685 ng/mL (reduction 31 %) (p = 0.01). In 7 (13 %) chosen had be increased unsatisfactory chelation therapy. For 21 patients, performed 19 these study: mean significantly from 16,8 mg/g dry tissue weight (± 8.3 mg/g weight) entry 10,8 mg/g 10.4 mg/g Of all exposed drug (n = 54), 28 (52 %) did not complete 12 month period most commonly AEs 28 % (n = 15) abnormal laboratory values 7 % (n = 4), respectively. common adverse events (≥ 10 % patients) suspected relationship diarrhea (n = 25, 46 %), nausea (n = 13, 24 %), upper abdominal pain (n = 8, 15 %), creatinine increase (n = 16, 30 %) rash (n = 5, 9 %). Adverse making adjustments or interruption necessary occurred 33 (61 %). Hematologic improvement according IWG criteria (2006) observed 6 (11 %). Initiation treatment IOL depending yields sufficient reduction excess indicated levels importantly MRI. profile comparable previous observations.

参考文章(26)
R. Arboretti, G. Tognoni, D. Alberti, Pharmacosurveillance and quality of care of thalassaemic patients. A large scale epidemiological survey. European Journal of Clinical Pharmacology. ,vol. 56, pp. 915- 922 ,(2001) , 10.1007/S002280000251
David P. Steensma, The role of iron chelation therapy for patients with myelodysplastic syndromes. Journal of The National Comprehensive Cancer Network. ,vol. 9, pp. 65- 75 ,(2011) , 10.6004/JNCCN.2011.0007
John M Bennett, None, Consensus statement on iron overload in myelodysplastic syndromes American Journal of Hematology. ,vol. 83, pp. 858- 861 ,(2008) , 10.1002/AJH.21269
Florian Nolte, Wolf-K Hofmann, Molecular mechanisms involved in the progression of myelodysplastic syndrome. Future Oncology. ,vol. 6, pp. 445- 455 ,(2010) , 10.2217/FON.09.175
Massimo Breccia, Paola Finsinger, Giuseppina Loglisci, Vincenzo Federico, Michelina Santopietro, Gioia Colafigli, Luigi Petrucci, Adriano Salaroli, Alessandra Serrao, Roberto Latagliata, Giuliana Alimena, Deferasirox treatment for myelodysplastic syndromes: “real-life” efficacy and safety in a single-institution patient population Annals of Hematology. ,vol. 91, pp. 1345- 1349 ,(2012) , 10.1007/S00277-012-1481-7
Christian Rose, Sabine Brechignac, Dominique Vassilief, Laurent Pascal, Aspasia Stamatoullas, Agnes Guerci, Dalila Larbaa, François Dreyfus, Odile Beyne-Rauzy, Marie Pierre Chaury, Lydie Roy, Stephane Cheze, Pierre Morel, Pierre Fenaux, Does iron chelation therapy improve survival in regularly transfused lower risk MDS patients? A multicenter study by the GFM Leukemia Research. ,vol. 34, pp. 864- 870 ,(2010) , 10.1016/J.LEUKRES.2009.12.004
Jong Wook Lee, Sung-Soo Yoon, Zhi Xiang Shen, Arnold Ganser, Hui-Chi Hsu, Dany Habr, Gabor Domokos, Bernard Roubert, John B Porter, EPIC Study Investigators, None, Iron chelation therapy with deferasirox in patients with aplastic anemia: a subgroup analysis of 116 patients from the EPIC trial. Blood. ,vol. 116, pp. 2448- 2454 ,(2010) , 10.1182/BLOOD-2010-01-261289
Norbert Gattermann, Eliezer A. Rachmilewitz, Iron overload in MDS—pathophysiology, diagnosis, and complications Annals of Hematology. ,vol. 90, pp. 1- 10 ,(2011) , 10.1007/S00277-010-1091-1
Peter L. Greenberg, Charles A. Koller, Z. Ioav Cabantchik, Ghulam Warsi, Tara Glynos, Carole Paley, Charles Schiffer, Prospective assessment of effects on iron-overload parameters of deferasirox therapy in patients with myelodysplastic syndromes Leukemia Research. ,vol. 34, pp. 1560- 1565 ,(2010) , 10.1016/J.LEUKRES.2010.06.013